Cargando…
Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
BACKGROUND: Patients with hypoalbuminemia often fail to respond to increased doses of loop diuretics. We therefore performed a post hoc analysis to investigate the pharmacological action of tolvaptan and whether it is dependent on the serum albumin level. METHODS: This analysis was based on four pre...
Autores principales: | Sakaida, Isao, Nakajima, Koji, Okita, Kiwamu, Hori, Masatsugu, Izumi, Tohru, Sakurai, Masaya, Shibasaki, Yoshiyuki, Tachikawa, Sayaka, Tsubouchi, Hidetsugu, Oka, Hiromi, Kobayashi, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592499/ https://www.ncbi.nlm.nih.gov/pubmed/25689936 http://dx.doi.org/10.1007/s00535-015-1052-5 |
Ejemplares similares
-
Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis
por: Sakaida, Isao, et al.
Publicado: (2016) -
Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020) -
Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021) -
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)